CytoDyn will host a webcast on March 8th to provide an overview of the CD12 test data and regulatory pathway for the US, UK, Canada, Philippines and Brazil

VANCOUVER, Wash., March 5, 2021 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTC.QB: CYDY)(“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix ™ (leronlimab-PRO 140), a CCR5 antagonist with potential for multiple therapeutic indications, today announced Nader Pourhassan, Ph.D., President , announced Scott Kelly, MD, Chairman and Chief Medical Officer, Mahboob Rahman, MD, Ph.D., Chief Scientific Officer, and Harish Seethamraju, MD, Medical Director for the Mount Sinai Lung Transplant Program, will host an investment community webcast on Monday, March 8, 2021.

Management will discuss the data from the recently completed Phase 3 study for critically to critically ill COVID-19 patients, the regulatory pathway with multiple countries, and updates to other clinical and business priorities.

Management will have approximately 90 minutes to answer questions posed online by analysts and investors.

Date: Monday March 8, 2021
Time: 1:00 p.m. PT / 4:00 p.m. ET
Dial in: None.
Ask:

• Questions can be submitted online to [email protected] prior to the webcast
• Questions can be submitted during the webcast using the webcast link below.

This is a “listen only” webcast that can be accessed via the CytoDyn corporate website at www.cytodyn.com in the Investors / IR Calendar section and is archived for 30 days. Attendees are encouraged to go to the website 15 minutes before the webcast begins to register, download, and install the required software. Please note that the website below is only operational approx. 60 minutes before the start of the webcast, which you can access via the following link:

https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/44014/indexl.html

The replay will be available approximately 60 minutes after the webcast ends and can be accessed through the link above until April 8, 2021.

CONTACTS
Investors:
Michael Mulholland
Office: 360.980.8524, ext. 102
[email protected]